Remove Cell Based Assays Remove Drugs Remove Webinar
article thumbnail

[Panel Webinar] How to tap into pharma’s $100bn digital transformation opportunity

The Pharma Data

Next-generation digital technologies are having an immense impact on the drug discovery process. The pharma industry is witnessing a steep rise in the use of AI-driven solutions in early-stage drug discovery, deep-learning technologies for compound screening, and lead identification and automation enhancements in the lab.

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Webinar | Ai At The Frontier: Empowering Early Career Professionals In Drug Discovery WEBINAR – ARE YOU CURIOUS ABOUT THE CUTTING-EDGE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND DRUG DISCOVERY? Are you curious about the cutting-edge intersection of Artificial Intelligence and Drug Discovery?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Bioanalysis Partner You Can Trust

Alta Sciences

Our evaluations count on essential biomarkers, like cytokines, complement factors, immune cell subtyping, and functional measurements. VIEW FACT SHEET Need more guidance? Send us a message.

article thumbnail

Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input

Agency IQ

For example, in describing how potency should be demonstrated for CGT products, the 2011 guidance simply stated that potency for gene therapy products is derived from “at least two biological activities for its potency: the ability to transfer a genetic sequence to a cell; and the biological effect of the expressed genetic sequence.”